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Abstract—CNS diseases such as Parkinson, schizophrenia, and attention deficit hyperactivity disorder (ADHD) are characterized by
a significant alteration of dopamine transporter (DAT) density. Thus, the development of compounds that are able to selectively
interact with DAT is of great interest. Herein we describe the design and synthesis of a new set of 3-aza-6,8-dioxabicyclo[3.2.1]oc-
tanes having a tropane-like structure with additional heteroatoms at positions 3 and 6. The compounds were evaluated for their
in vitro receptor binding properties toward human dopamine (hDAT) and serotonin (hSERT) transporters using [3H]WIN35,428
and [3H]citalopram as specific radioligands, respectively. Biological assays revealed that some compounds having the N-3 atom
substituted with aryl groups possess significant affinity and selectivity for monoamine transporters, and in particular, compound
5d displayed an IC50 of 21 nM toward DAT, and a good selectivity toward SERT (IC50 = 1042 nM). These results suggest that
3-aryl-3-aza-6,8-dioxabicyclo[3.2.1]octanes may represent a new class of DAT ligands.
 2006 Elsevier Ltd. All rights reserved.
1. Introduction
Abnormalities in the dopamine neurotransmitter system
are implicated in several psychomotor disorders such as
Parkinson’s disease, schizophrenia, attention deficit
hyperactivity disorder (ADHD), and depression.1–4 In
particular, in vitro studies of human Parkinsonian pa-
tients showed that dopamine transporter (DAT) striatal
expression is considerably depleted, and the extent of
depletion is correlated with the progression of the dis-
ease.5,6 In contrast, ADHD has been demonstrated to
be accompanied by a significant increase in the dopa-
mine transporter density.7
The investigation of dopaminergic agents and, in partic-
ular, selective dopamine transporter ligands, has
received considerable attention, especially for the devel-
opment of new imaging agents which could be biochem-
ical probes for the measurement of the density of
presynaptic dopamine transporter sites by emission
tomography. This could be a potentially valuable tech-
nique for the diagnosis, management of treatment, and
study of the pathogenesis of addictive and psychomotor
disorders in humans.
Moreover, as it has been recognized that DAT plays a
key role in the modulation of postsynaptic dopamine
levels, and as cocaine is able to bind to DAT and to
inhibit the dopamine reuptake,8–11 much interest has
been oriented toward the generation of molecules,
respectively, capable of inhibiting or favoring dopamine
reuptake in presynaptic neurons by selective interaction
with DAT, as they may contribute to the generation of
new therapeutics against CNS disorders. Although stud-
ies of structure–activity relationships (SAR) did not pro-
vide a comprehensive picture of the binding interaction
to DAT at molecular level yet, studies on cocaine and its
tropane analogues (see Fig. 1)8,12–26 showed that two
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take activities: (1) the presence of an aromatic ring con-
nected directly or indirectly to the 3 position of the
tropane ring, and the nature of the aromatic substitu-
ents, strongly influences the dopamine transporter li-
gand recognition. Specifically, an increase in the
electronic density on this part of the molecule is associ-
ated with high DAT affinity; (2) the relative position of
the aromatic group at position 3 and of the substituent
at position 2.26 In fact, it has been shown that the orien-
tation of the 3-aryl moiety in either a-(endo) or b-(exo)
configuration modulates the selectivity of these com-
pounds toward DAT with respect to other monoamine
transporters.27 Moreover, the orientation of the aromat-
ic ring in a more planar relationship with the tropane
skeleton due to the presence of a double bond at C-2
and C-3 greatly enhances biological selectivity.24 Still,
2a-configuration of the substituent in the tropane ring
leads to much less active DAT inhibitors.28–30 More-
over, it was described in literature that the presence of
a nitrogen atom at 8-position of tropanes is not an abso-
lute requisite for binding to DAT, and different 3-phe-
nyltropanes bearing either an oxygen or a carbon
atom at 8-position (Fig. 1) have been reported to main-
tain a good affinity.27,31,32
Among all DAT inhibitors based on tropane-like scaf-
folds reported to date, only few modifications of the
core structure have been investigated. Recently, a nice
example of a new scaffold having the nitrogen atom
shifted from position 8 to 6 has been reported, which
showed interesting inhibiting properties compared to
cocaine.33 We reasoned that, since there are no exam-
ples in literature describing the introduction of more
than one heteroatom in the scaffold, especially in the
key position 3 bearing an aromatic substituent, it
would have been noteworthy to use a new molecule
having a tropane-like structure to test the stereoelec-
tronic features correlated to the binding potency to-
ward DAT, thus providing new chemical insights into
the design of DAT inhibitors. During the last five years
we have been developing a new class of enantiopure 3-
aza-6,8-dioxa-bicyclo[3.2.1]octane scaffolds as c/d bicy-
clic amino acids named BTAa,34,35 which are obtained
from the combination of tartaric acid and a-amino car-
bonyl derivatives. More recently, a new set of proline-
like bicyclic a-amino acids, named BG(g)S(s), has been
reported, which derive from the combination of glycer-
aldehyde and serinol derivatives.36 Since they present
the carboxyl moiety of BTAa formally shifted from po-
sition 7 to 4, we envisioned the possibility of using the
Bgs stereoisomer, obtained from L-glyceraldehyde and
D-serine derivatives, as tropane-mimetics containing
three heteroatoms in the core structure, and possessing
the correct absolute configuration with respect to co-
caine. Indeed, these compounds show structural simi-
larity with the bicyclic structure of tropane, and
possess the correct configuration at C-4 carbon atom
having the carbomethoxy group oriented in 4-exo con-
figuration (Fig. 2).
Moreover, the presence of heteroatoms might contribute
to decreasing the non-specific binding of these molecules
in the brain, which is a limiting factor for their possible
use as radiolabeled imaging agents. More generally,
such molecules were used to test the effect on binding
potency and selectivity of the presence of two additional
heteroatoms at positions 3 and 6 of the scaffold with re-
spect to the tropane structure. Therefore, a collection of
suitably functionalized Bgs molecules having different
substituents at the nitrogen atom was prepared in order
to establish how such heteroatom might influence the
topology of the aromatic ring in terms of binding
affinity.
Finally, the stereoelectronic properties were computed,
and analyzed together with the affinity results in order
to draw a rationale connected with the structural
features of the new proposed scaffolds.
2. Results and discussion
2.1. Chemistry
Fmoc-Bgs amino acid was obtained in 24% yield accord-
ing to the previously reported method.36 After treatment
with diazomethane, the corresponding N-Fmoc-amino
Figure 2. 2-exo-Tropane-based DAT inhibitors (left) and Bgs-derived
compounds (right).
Figure 1. Structures of cocaine and 3-phenyltropane-based compounds as DAT inhibitors.27,32
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ester was obtained in 91% yield,37 and further deprotec-
ted using diethylamine in dry acetonitrile, to afford H-
Bgs-OMe 1 in quantitative yield.
Treatment of 1 (Scheme 1) with benzoyl chloride in the
presence of triethylamine gave the corresponding N-ben-
zoyl-Bgs compound 2 (Scheme 1, path i), whereas p-bro-
mobenzyl and benzyl groups were introduced by
reductive amination of the corresponding functionalized
benzaldehyde using NaBH(OAc)3 in 1,2-dichloroethane
(Scheme 1, path ii), thus giving 3 and 4, respectively.38
Low yields of reductive aminations of 1 (50% and
57%) were probably due to steric hindrance and to the
poor nucleophilicity of the N-3 associated with the pres-
ence of the ester group.
The insertion of an aromatic ring directly bound to the
nitrogen atom proved to be more challenging (Scheme 1,
path iii). The effect of steric hindrance in the arylation of
secondary amines having substituents adjacent to the
amine function has been reported in the literature, and
low yields were accounted for the reaction.39–42 Initially,
arylation of the amine group using aryl bromides in
refluxing toluene for 20 h and in the presence of BIN-
AP/Pd(OAc)2 as catalyst failed,
39 and only the unre-
acted starting material was recovered. Attempts at
increasing the conversion using 1,4-dioxane as solvent
did not work.
The choice of different catalytic systems, depending
on the aryl bromide used (i.e., Pd2(dba)3/BINAP,
PdCl2(dppf)), in higher amounts, as reported in the liter-
ature,43 was likewise unsuccessful. In contrast, arylation
of 1 using arylboronic acids and Cu(OAc)2 under an
oxygen atmosphere in dry CH2Cl2, and in the presence
of a base gave the desired products, though in low yields
(5–30%, see Table 1). The use of a base such as triethyl-
amine or pyridine was found to be crucial, as the reac-
tion failed when a base was absent.
As reported in the literature, the presence of molecular
oxygen in copper-promoted N-arylation reactions has
been hypothesized to facilitate the oxidation of the inter-
mediate Cu(II)- to the Cu(III)-complex, which can
undergo more facile reductive-elimination than the
Cu(II)-complex to form the desired products.41 There-
fore, the effect of raising oxygen pressure on the reaction
was evaluated, but only a modest increase in the final
yield was observed, and in some cases epimerization at
C-4 stereocenter occurred. The use of pyridine in place
of triethylamine, in refluxing CH2Cl2, gave the desired
products in modest yield, and epimerization at C-4
Scheme 1. Reagents and conditions: (i) PhCOCl, Et3N, dry THF, rt, overnight; (ii) benzaldehyde or p-Br-benzaldehyde, NaBH(OAc)3, DCE, rt,
overnight; (iii) ArB(OH)2, base, dry CH2Cl2, Cu(OAc)2, 4 A˚ molecular sieves, O2, 25–50 C, 24–72 h.
Table 1. N-Arylation reaction of 1 with selected arylboronic acids using cupric acetate
Compound Boronic acid T (C) PO2 (atm) Time (h) Base Yield (%) exo:endoa
1 4-Acetyl-phenyl 25 1 24 Et3N 5 exo only
2 4-Bromo-phenyl 25 5 24 Et3N 27 1:1
3 4-Iodo-phenyl 25 17 24 Et3N 25 1:1
4 4-Chloro-phenyl 50 17 24 Et3N 26 2:3
5 3,4-Dichloro-phenyl 50 1 72 Py 18 1:2
6 2-Naphthyl 50 1 72 Py 15 1:2
7 Phenyl 30 17 40 Py 14 exo only
8 4-Fluorophenyl 30 17 40 Py 30 exo only
a Based on the yield of isolated products.
5112 N. Cini et al. / Bioorg. Med. Chem. 14 (2006) 5110–5120
Au
th
or
's 
  p
er
so
na
l   
co
py
carbon atom of the scaffold was observed in variable ex-
tent, even at one atmosphere of oxygen. Finally, when
both temperature and reaction time were lowered, 4-
endo products were not obtained using pyridine, even
at high pressures of oxygen. Thus, it was found that epi-
merization at C-4 could be due to different combinations
of reaction conditions, and that a marked improvement
of the yield was never observed. All the obtained dia-
stereomeric compounds having the carbomethoxy group
in 4-endo configuration were easily separated from the
corresponding 4-exo isomers by chromatography. Both
isomers were then subjected to binding assay to gain
further insight on the influence of the orientation of
the carbomethoxy group within the 3-aza-6,8-diox-
a[3.2.1]bicyclic scaffold on binding affinity and selectivi-
ty for the DAT.
Structural assignment of the configuration at C-4 stereo-
center for N-aryl compounds 5a–m was achieved by
comparison of the chemical shift data and the J values
of H-4 and H-5 protons, as NOE experiments were
not diagnostic for such structural determination. Specif-
ically, it was found a typical NMR pattern of the H-4
proton for 4-exo- and 4-endo-structures with respect to
H-5, and the corresponding J value proved to be depen-
dent upon the relative positions of the two protons
(Fig. 3 and Table 2). All the 4-exo-structures displayed
a chemical shift of H-4 between 4.59 ppm and
4.34 ppm, and a J value between 0 and 2 Hz, whereas
4-endo stereoisomers, as well as showing similar chemi-
cal shift values for H-5, displayed an upfield shift of
H-4 between 4.21 and 4.03 ppm, and a greater J value
between 2.8 and 3.4 Hz, indicating a lower dihedral an-
gle between H-4 and H-5.
2.2. Biology
The assays were performed on crude membrane receptor
preparations originated from recombinant human dopa-
mine transporter (hDAT) and from recombinant human
serotonin transporter (hSERT) transfected into CHO
and HEK293 cells, respectively.44 The IC50 values of
Bgs scaffolds toward DAT and SERT are reported in
Table 3, and were assayed by using a competitive dis-
placement of a specific radioligand for each transporter
([3H]WIN35,428 8 nM for DAT and [3H]citalopram
1 nM for SERT).45,46 Competition studies were carried
out using a fixed concentration of the radioligand and
a range of concentrations between 100 lM and 1 nM
of test compounds. All active Bgs molecules inhibited
[3H]WIN35,428 and [3H]citalopram binding in a concen-
tration-dependent manner.
2.3. Discussion
In the present study, we report on the effect of replacing
the tropane ring with a 3-aza-6,8-dioxa[3.2.1]bicyclic
scaffold on binding affinity and selectivity for the dopa-
mine transporter. Selected functional groups were intro-
duced at position 3 of the scaffold. Specifically benzoyl,
Fmoc, substituted benzyl, and aryl derivatives were
introduced on Bgs in order to evaluate their effect on
the receptor binding affinity. The lack of binding affinity
of Fmoc-, benzoyl- (2), and benzyl- (3 and 4) derivatives
(Table 3) could be probably due to the wrong orienta-
tion of the phenyl ring with respect to the correct geom-
etry for the interaction with the hydrophobic pocket of
DAT and SERT receptors. Moreover, the inactivity of
2, 3, and 4 indicated a moderate interaction of N-3 atom
with DAT, as a marked difference in nitrogen nucleophi-
licity (benzoyl vs benzyl) did not evidence variations in
the inhibitory potency. Indeed, only some of N-aryl-
functionalized compounds 5a–m proved to display affin-
ity toward DAT, as showed in Table 2. Compound 5d,
having 3,4-dichloro-phenyl substituent at position 3,
displayed low nanomolar activity toward DAT
(IC50 = 21 nM), being about 8-fold more potent than
the other bioactive N-aryl-Bgs. The higher SERT bind-
ing affinity of N-(2-naphthyl)-Bgs-OMe (5a) with respect
to DAT was striking, and could be due to a higher steric
hindrance associated with the hydrophobic pocket of
DAT receptor compared to the SERT binding site,
which is larger enough to accommodate a naphthyl
group. More generally, the 4-endo scaffolds were totally
inactive toward SERT and showed poor affinity toward
DAT with respect to the corresponding 4-exo isomers, in
accordance with the reported evidence that the corre-
sponding stereochemistry change in the tropane ring
leads to a strong affinity decrease.28–30
The presence of functional groups on the aromatic ring
proved to influence the affinity (see 5d, 5f, 5h, and 5j
compared to 5c, 5l, and 5m). In particular, for both 4-
endo and 4-exo isomers, different functionalization of
the phenyl ring with halogens resulted in the same trend
of DAT affinity, being 3,4-Cl2 > 4-Cl > 4-Br > 4-I > 4-
F, 4-H. In general, Bgs compounds were less potent
compared to the corresponding 8-oxatropanes,27 howev-
er a remarkable selectivity toward SERT was observed
in variable extent. As reported by Meltzer, the heteroat-
om at position 8 directs the ligand orientation in the
dopamine transporter site, as the length of the hydrogen
bond between such heteroatom and the amino acid in
the receptor binding site influences the position of the
3-aryl ring in the hydrophobic pocket, and the deeper
placement of the 3-aryl substituent into the acceptor site
of DAT, the higher potency results. Given that Bgs com-
pounds show the same heteroatom at position 8 com-
pared to 8-oxatropanes, the different potency could be
Figure 3. 4-exo- and 4-endo-Bgs structures.
Table 2. NMR data for 4-exo- and 4-endo-aryl-Bgs compounds
Structure d H-5 (ppm) d H-4 (ppm) 3J4,5 (Hz)
4-exo-COOMe 5.88–5.82 4.59–4.34 2.0–0
4-endo-COOMe 5.84–5.80 4.21–4.03 3.4–2.8
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due to an altered fitting within the receptor, as a conse-
quence of the presence of O-6 and N-3 heteroatoms in
the bicyclic structure. Moreover, the flipping capability
of the nitrogen atom could emphasize both the flexibility
and the direction of the aromatic group, and either a
share of O-6 in the interaction of O-8 with the transport-
er, or an additional interaction of O-6 within the recep-
tor site could impart a twist with respect to the typical
orientation of the tropane skeleton determining an
uncorrected position of the aryl moiety. An electronic
component could exert a role to the selectivity and the
binding affinity toward DAT, too, due to the presence
of the nitrogen atom at position 3 and also of oxygen
atom at position 6, thus altering the overall charge dis-
tribution of the scaffold, as outlined in Section 3.4.
2.4. Computational analysis
In an attempt to form a clearer basis to the potential
mode of binding of the new compounds, we looked at
the electronic and spatial properties of these compounds
in the molecular modeling package Spartan.47 Specifical-
ly, lead compound 5d was modeled in comparison to the
known 8-oxatropane O-1072, to test the stereoelectronic
differences of the two molecules.
Conformational searches of O-1072 and 5d were car-
ried out using Monte Carlo method within MMFF94
force field,48 and the AM149 semiempirical method
was used to optimize the global minimum conformer.
Electrostatic potential maps and atomic electrostatic
charge densities (Table 4) for the minimum energy
conformers of O-1072 and 5d were computed using
ab initio quantum chemical procedures at the 3-21G*
level50 to gain insights on the basis for the stereoelec-
tronic features leading to a different binding interac-
tion to the DAT. The superimposition of the two
global minimum structures of 5d and O-1072 gave a
RMS value of 0.162 A˚, and confirmed that the best
orientation of the aromatic ring for Bgs scaffolds
was found in N-aryl-Bgs compounds (Fig. 4). More-
over, structural data of the two compounds showed
strict resemblance with respect to the bicyclic struc-
ture, and the orientation of the aromatic ring turned
out to be similar.
With regard to the electronic properties of N-aryl-Bgs
compounds, the presence of a heteroatom-rich structure
modified the electrostatic potential of the scaffold,
whereas the electron density at the aromatic ring re-
mained substantially unchanged, as shown in Figure 5.
In particular, the presence of oxygen and nitrogen atoms
at positions 6 and 3 of 5d, respectively, contributed to
increase the electron density in such regions of the mol-
ecule, thus allowing additional interactions or variations
of the molecular recognition about the receptor, which
Table 3. Inhibition of [3H]WIN35,428 binding to hDAT and [3H]citalopram binding to hSERT by Bgs scaffolds
Compound R C-4 substituent IC50
a (nM) Selectivityb
DAT SERT
2 Benzoyl COOMe >10,000 >10,000 —
— Fmoc COOMe >10,000 >10,000 —
4 Benzyl COOMe >10,000 >10,000 —
3 4 0-Br-Benzyl COOMe >10,000 >10,000 —
5c 4 0-CH3CO–Ph COOMe >10,000 >10,000 —
5d 3 0,4 0-Cl2–Ph COOMe 21 1042 50
5e 3 0,4 0-Cl2–Ph 4-endo-COOMe 267 >10,000 >37
5a 2 0-Naphthyl COOMe 5456 598 0.11
5b 2 0-Naphthyl 4-endo-COOMe >10,000 >10,000 —
5f 4 0-Cl–Ph COOMe 163 >10,000 >61
5g 4 0-Cl–Ph 4-endo-COOMe 1107 >10,000 >9
5h 4 0-I–Ph COOMe 219 3159 14.4
5i 4 0-I–Ph 4-endo-COOMe >10,000 >10,000 —
5j 4 0-Br–Ph COOMe 188 2218 12
5k 4 0-Br–Ph 4-endo-COOMe 5320 >10,000 >1.8
5l Ph COOMe >10,000 >10,000 —
5m 4 0-F–Ph COOMe >10,000 >10,000 —
a IC50 values are expressed as a means of three experiments performed in triplicate.
b Selectivity results from the ratio of SERT to DAT IC50 values.
Table 4. Atomic electrostatic charge densities for O-1072 and 5d
calculated at the 3-21G* level
Atoma O-1072 5d
C-5 (O-1072)/C-1 (5d) 0.38 0.25
C-4 (O-1072)/C-2 (5d) 0.43 0.17
C-3 (O-1072)/N-3 (5d) 0.54 0.12
C-2 (O-1072)/C-4 (5d) 0.64 0.53
C-1 (O-1072)/C-5 (5d) 0.36 0.67
C-7 (O-1072)/O-6 (5d) 0.17 0.53
C-6 (O-1072)/C-7 (5d) 0.16 0.15
O-8 0.57 0.56
C@O 1.19 1.16
C@O 0.67 0.65
C-1 0 0.12 0.25
C-20 0.27 0.23
C-30 0.15 0.08
C-40 0.03 0
C-50 0.08 0.06
C-60 0.21 0.40
m-Cl 0.07 0.08
p-Cl 0.10 0.07
a See Figure 2 for the numeration of atoms of O-1072 and 5d.
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in turn could affect affinity and selectivity toward DAT
(Table 4).
Moreover, the dipolar moment of the 5d compared to
O-1072 turned out to be different both in the absolute
value and in the orientation (5d: l = 2.82 D, O-1072:
l = 3.41 D; 5d: x = 0.489, y = 2.279, z = 1.588; O-
1072: x = 1.459, y = 0.981, z = 2.922). The electronic
distribution was different with respect to the atoms of
the bicyclic structure, except for C-4, C-1, and O-8 for
5d, whereas only the C ipso of the aromatic ring (C-1 0)
seemed to experience different electrostatic charge densi-
ties, due to the nature of the vicinal atom at position 3
(Table 4). Thus, modeling calculations supported the
hypothesis that a different electrostatic charge distribu-
tion within the bicyclic structure of 5d compared to O-
1072, as a consequence of the presence of two additional
heteroatoms, could contribute to modulate the affinity
and selectivity of 5d toward DAT. Ultimately, the differ-
ences in the molecular electrostatic potential of 5d and
O-1072 contributed to assume the existence of addition-
al electrostatic interactions of O-6 with DAT, in order to
explain the biological outcome of this new class of
compounds.
2.5. Conclusion
The synthesis of a collection of 3-aza-6,8-dioxabicy-
clo[3.2.1]octane scaffolds, which possessed affinity
and selectivity toward the dopamine transporter, was
developed. In particular, the investigation of different
substituents at nitrogen atom suggested the strict rela-
tionship between the topology of the aromatic group
and the binding affinity and selectivity toward DAT
and SERT monoamine transporters. Only N-aryl-
Bgs-OMe molecules showed binding properties, in
analogy with 3-aryl-tropane molecules, and specifical-
ly, compound 5d possessing a 3,4-dichloro-phenyl
group and 5a having a naphthyl group were the most
potent ligands for DAT and SERT, respectively. All
the 4-endo isomers showed poor activity toward
DAT with respect to the corresponding 4-exo mole-
cules. In general, N-aryl-Bgs compounds showed low
potency toward DAT, but nice selectivity was ob-
served, suggesting a possible role of the two heteroa-
toms in exerting stereoelectronic effects responsible
for a different arrangement of the scaffold within the
active site of the transporters. Molecular modeling cal-
culations on 5d and on the reference compound O-
1072 revealed that the two compounds showed close
similarity with respect to the bicyclic structure and
to the orientation of the aromatic ring. The heteroat-
om-rich structure of N-aryl-Bgs 5d modified the elec-
trostatic potential of the bicyclic tropane scaffold,
whereas the electron density at the aromatic ring re-
mained substantially unchanged, indicating that the
electrostatic charge distribution within the bicyclic
structure of 5d may modulate the affinity toward
DAT, and the SERT to DAT selectivity as a conse-
quence of a less favorable interaction at the SERT.
Hence, Bgs scaffolds proved to be promising com-
pounds for the development of new DAT ligands, as
the synthesis is simple and occurs with complete
stereochemical control.
3. Experimental
3.1. General
Melting points are uncorrected. Chromatographic sepa-
rations were performed on silica gel using flash-column
techniques; Rf values refer to TLC carried out on 25 mm
silica gel 60 F254 plates with the same eluant indicated
for column chromatography. 1H and 13C spectra were
recorded with a Varian Gemini 200 MHz or Varian
Mercury 400 MHz instrument using CDCl3 solutions
unless otherwise stated. EI-mass spectra were carried
out at 70 eV ionizing voltage using a Shimadzu
GCMS-QP5050 spectrometer. IR spectra were recorded
with a Perkin-Elmer FT-IR-1600 spectrophotometer.
Elemental analyses were obtained with a Perkin-Elmer
2400/2 C analyzer. Radioactivity was measured with a
Perkin-Elmer TopCount NXT microplate scintillation
counter. THF was distilled from Na/benzophenone.
CH2Cl2 was distilled from CaH2. All reactions requiring
anhydrous conditions were performed in oven-dried
glassware.
Figure 4. Superimposition of 5d with O-1072 (yellow).
Figure 5. Three-dimensional isopotential contours of molecular elec-
trostatic potential at 20 kcal/mol for O-1072 (left) and compound 5d
(right).
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[3H]WIN35,428 in ethanol (1 mCi/mL, specific activity
87 Ci/mmol, chemical purity 97%) and [3H]citalopram
in ethanol (1 mCi/mL, specific activity 84.2 Ci/mmol,
chemical purity 97%) were purchased from Perkin-El-
mer Life Sciences (Boston, MA). Crude membrane
receptor preparations from cells that express recombi-
nant human dopamine transporter (hDAT) and recom-
binant human serotonin transporter (hSERT) were
obtained from Perkin-Elmer Life Science (Boston,
MA). The receptor concentration (Bmax) ranged from
4.2 to 1.7 and from 6.8 and 4.8 pmol/mg protein for
hDAT and hSERT, respectively.
3.2. Chemistry
3.2.1. (1R,4R,5S)-6,8-Dioxa-3-aza-bicyclo[3.2.1]octane-
4-exo-carboxylic acid methyl ester (1). To a solution of
Fmoc-Bgs-OH (1.94 g, 5.09 mmol), prepared as report-
ed,36 in MeOH was dropwise added at 0 C a freshly
prepared ethereal solution of CH2N2 until a permanent
yellow color persisted. After solvent evaporation, the
corresponding methyl ester (1.83 g, 91%) was obtained
as an oil. 2:3 mixture of rotamers 1H NMR d 7.75 (d,
J = 7.4 Hz, 2H), 7.54 (m, 2H), 7.43–7.26 (m, 4H), 5.80
and 5.76 (s, 1H), 4.60–4.40 (m, 4H), 4.28 (m, 1H),
3.99–3.80 (m, 3H), 3.76 and 3.73 (s, 3H), 3.57–3.47 (m,
1H); 13C NMR d 168.1 (s), 156.2 and 155.9 (s), 143.5
(s, 2C), 141.2 (s, 2C), 127.7 (d, 2C), 127.1 (d, 2C),
124.9 and 124.8 (d, 2C), 120.0 (d, 2C), 98.7 and 98.3
(d), 71.8 and 71.3 (d), 67.8 (t) and 67.7 (t), 67.1 (t) and
67.0 (t), 60.1 and 59.7 (d), 52.5 and 52.4 (q), 47.2 and
47.1 (d), 46.4 and 45.9 (t); MS m/z 395 (M+, 3), 179
(100), 172 (19), 113 (8), 59 (38). Successively, to a solu-
tion of Fmoc-Bgs-OMe (1.68 g, 4.24 mmol) in dry aceto-
nitrile (50 mL) was added Et2NH (1.76 mL, 17.0 mmol),
then the solution was stirred at room temperature for
3.5 h. After evaporation of the solvent, the residue was
dissolved in MeOH and stirred for 30 min. The white
solid was filtered off and the solvent was removed, then
the crude product was purified by flash chromatography
(EtOAc/pet. ether, 2:1 then MeOH) to give pure 1
(720 mg, 98%) as an oil. ½a27D +34.9 (c 0.54, CHCl3);
1H NMR d 5.72 (s, 1H), 4.45 (m, 1H), 4.18 (d,
J = 7.0 Hz, 1H), 3.80 (m, 1H), 3.77 (s, 3H), 3.45 (s,
1H), 3.42 (d, J = 11.4 Hz, 1H), 2.64 (d, J = 11.4 Hz,
1H), 1.98 (br, 1H); 13C NMR d 170.5 (s), 99.9 (d),
73.5 (d), 67.0 (t), 60.0 (d), 52.0 (q), 46.0 (t); MS m/z
173 (M+, 15), 128 (100), 114 (47), 86 (48), 59 (15). Anal.
Calcd for C13H17NO3: C, 66.36; H, 7.28; N, 5.95.
Found: C, 66.31; H, 7.22; N, 5.86.
3.2.2. (1R,4S,5S)-N-(Benzoyl)-6,8-dioxa-3-aza-bicy-
clo[3.2.1]octane-4-exo-carboxylic acid methyl ester (2).
To a solution of 1 (50 mg, 0.289 mmol) in dry THF were
added dropwise at 0 C Et3N (77.2 lL, 0.462 mmol) and
benzoyl chloride (41 lL, 0.289 mmol). The mixture was
stirred at room temperature overnight, then brine was
added and the two phases were separated. The aqueous
layer was extracted with CH2Cl2 twice, and then the
organic phases were dried (Na2SO4) and evaporated to
give pure 2 (73 mg, 91%) as an oil. ½a23D 14.51 (c
0.84, CHCl3); 1:1 mixture of rotamers
1H NMR d 7.37
(m, 5H), 5.89 (d, J = 1.8 Hz, 1H) and 5.72 (d,
J = 2.2 Hz, 1H), 5.14 (s, 1H), 4.65 (m, 1H), 4.47–4.24
(m, 2H), 4.10 (d, J = 7.4 Hz, 1H), 3.95–3.87 (m, 2H),
3.84–3.71 (m, 4H), 3.82 (s, 3H) and 3.75 (s, 3H), 3.43
(m, 1H); 13C NMR d 172.2 (s), 167.8 (s), 134.6 (s),
130.1 (d), 130.0 (d), 128.7 (d), 128.6 (d), 126.7 (d),
126.6 (d), 99.0 (d), 98.4 (d), 72.3 (d), 71.6 (d), 67.3 (t),
66.8 (t), 52.7 (q), 49.9 (d), 44.1 (t); MS m/z 277 (M+,
27), 219 (4), 105 (100), 77 (71); IR (CHCl3) 1746,
1710, 1654, 1417 cm1. Anal. Calcd for C14H15NO5:
C, 60.64; H, 5.45; N, 5.05. Found: C, 60.79; H, 5.38;
N, 4.98.
3.2.3. (1R,4S,5S)-N-(4-Bromo-benzyl)-6,8-dioxa-3-aza-
bicyclo[3.2.1]octane-4-exo-carboxylic acid methyl ester
(3). Compound 1 (70 mg, 0.404 mmol) and 4-bromo-
benzaldehyde (75.2 mg, 0.404 mmol) were mixed in
1,2-dichloroethane (2.0 mL) and then treated with sodi-
um triacetoxyborohydride (120 mg, 0.566 mmol). The
mixture was stirred under a nitrogen atmosphere over-
night. The reaction mixture was quenched by adding
aqueous saturated NaHCO3 and the product was
extracted with CH2Cl2. The organic layer was dried
(Na2SO4) and the solvent was evaporated to give the
crude free base. Purification by flash chromatography
(EtOAc/pet. ether, 1:3, Rf = 0.47) gave 3 (69 mg, 50%)
as an oil. ½a24D 11.34 (c 0.42, CHCl3); 1H NMR
(400 MHz) d 7.43 (d, J = 8.4 Hz, 2H), 7.21 (d,
J = 8.4 Hz, 2H), 5.67 (d, J = 2.0 Hz, 1H), 4.51 (d,
J = 5.2 Hz, 1H), 4.10 (d, J = 6.0 Hz, 1H), 3.87 (d,
J = 14.0 Hz, 1H), 3.76 (m, 2H), 3.75 (s, 3H), 3.51 (d,
J = 2.0 Hz, 1H), 3.35 (d, J = 11.2 Hz, 1H), 2.44 (d,
J = 11.2 Hz, 1H); 13C NMR (100 MHz) d 169.9 (s),
137.5 (s), 131.5 (d), 130.2 (d), 121.0 (s), 99.7 (d), 73.2
(d), 67.6 (t), 65.2 (d), 57.3 (t), 51.5 (q), 50.6 (t); MS m/
z 344 (M+ + 2, 0.8), 342 (M+, 1), 298 (7), 296 (7), 284
(15), 282 (17), 171 (77), 169 (78), 84 (100); IR (CHCl3)
1740, 1601, 1486 cm1. Anal. Calcd for C14H16BrNO4:
C, 49.14; H, 4.71; N, 4.09. Found: C, 49.18; H, 4.69;
N, 4.01.
3.2.4. (1R,4S,5S)-N-(Benzyl)-6,8-dioxa-3-aza-bicy-
clo[3.2.1]octane-4-exo-carboxylic acid methyl ester (4).
Compound 4 was prepared as described for 3. Purifica-
tion by flash chromatography (EtOAc/pet. ether, 1:3,
Rf = 0.44) gave pure 4 (172 mg, 57%) as an oil. ½a23D5.17 (c 0.69, CHCl3); 1H NMR d 7.28 (m, 5H), 5.67
(d, J = 2 Hz, 1H), 4.51 (m, 1H), 4.13 (d, J = 6.2 Hz,
1H), 3.84 (m, 3H), 3.75 (s, 3H), 3.53 (d, J = 2 Hz, 1H),
3.36 (d, J = 11.4 Hz, 1H), 2.46 (d, J = 11.4 Hz, 1H);
13C NMR d 170.1 (s), 138.5 (s), 128.5 (d), 128.4 (d),
127.2 (d), 99.8 (d), 73.3 (d), 67.6 (t), 65.3 (d), 57.9 (t),
51.4 (q), 50.6 (t); MS m/z 263 (M+, 6), 218 (5), 204
(11), 158 (2), 105 (20), 91 (100); IR (CHCl3) 1740,
1602, 1494, 1451, 1250 cm1. Anal. Calcd for
C14H17NO4: C, 63.87; H, 6.51; N, 5.32. Found: C,
64.02; H, 6.42; N, 5.24.
3.2.5. General procedure for N-arylation. A 150 mL
stainless steel autoclave was charged with H-Bgs-OMe
1 (50 mg, 0.289 mmol, 1 equiv) dissolved in dry CH2Cl2
(2 mL), the appropriate boronic acid (0.867 mmol,
3 equiv), anhydrous cupric acetate (0.578 mmol,
2 equiv), base (0.867 mmol, 3 equiv), 4 A˚ molecular
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sieves, and then oxygen up to the desired atmosphere
(see Table 1). The vessel was stirred and heated. After
filtration over Celite of the reaction mixture, the solvent
was evaporated and the crude oil was purified by flash
chromatography.
3.2.6. (1R,4S,5S)-N-Naphthalen-2-yl-6,8-dioxa-3-aza-bi-
cyclo[3.2.1]octane-4-exo-carboxylic acid methyl ester (5a)
and (1R,4R,5S)-N-naphthalen-2-yl-6,8-dioxa-3-aza-bicy-
clo[3.2.1]octane-4-endo-carboxylic acid methyl ester (5b).
Compounds 5a and 5b were obtained as orange oils in
5% and 10% yield, respectively. Compound 5a:
Rf = 0.6 (EtOAc/pet. ether, 1:1);
1H NMR d 7.84–7.64
(m, 3H), 7.44–7.28 (m, 2H), 7.08–7.00 (m, 2H), 5.88 (s,
1H), 4.78 (m, 1H), 4.59 (s, 1H), 4.10 (d, J = 6.6 Hz,
1H), 3.91–3.74 (m, 2H), 3.66 (s, 3H), 3.5–3.43 (m, 1H);
MS m/z 299 (M+, 11), 58 (100). Anal. Calcd for
C17H17NO4: C, 68.21; H, 5.72; N, 4.68. Found: C,
67.97; H, 5.62; N, 4.63.
Compound 5b: Rf = 0.4 (EtOAc/pet. ether, 1:1);
1H
NMR d 7.78–7.63 (m, 3H), 7.40–7.29 (m, 2H), 7.12–
6.94 (m, 2H), 5.83 (d, J = 3.2 Hz, 1H), 4.79 (m, 1H),
4.46 (d, J = 8.0 Hz, 1H) 4.21 (d, J = 3.2 Hz, 1H), 3.95
(m, 1H), 3.72 (s, 3H), 3.55 (m, 1H), 3.41(m, 1H); MS
m/z 299 (M+, 6), 178 (100). Anal. Calcd for
C17H17NO4: C, 68.21; H, 5.72; N, 4.68. Found: C,
68.16; H, 5.68; N, 4.61.
3.2.7. (1R,4S,5S)-N-(4-Acetyl-phenyl)-6,8-dioxa-3-aza-
bicyclo[3.2.1]octane-4-exo-carboxylic acid methyl ester
(5c). A yellow oil was obtained in 5% yield. Rf = 0.14
(Et2O/pet. ether, 2:1).
1H NMR d 7.89 (d, J = 9.1 Hz,
2H), 6.72 (d, J = 9.1 Hz, 2H), 5.88 (s, 1H), 4.77 (m,
1H), 4.49 (s, 1H), 4.03 (d, J = 7.0 Hz, 1H), 3.88 (m,
1H), 3.71 (s, 3H), 3.50–3.43 (m, 2H), 2.52 (s, 3H); MS
m/z 291 (M+, 19.1), 146 (100). Anal. Calcd for
C15H17NO5: C, 61.85; H, 5.88; N, 4.81. Found: C,
61.94; H, 5.92; N, 5.02.
3.2.8. (1R,4S,5S)-N-(3,4-Dichloro-phenyl)-6,8-dioxa-3-
aza-bicyclo[3.2.1]octane-4-exo-carboxylic acid methyl
ester (5d) and (1R,4R,5S)-N-(3,4-dichloro-phenyl)-6,8-
dioxa-3-aza-bicyclo[3.2.1]octane-4-endo-carboxylic acid
methyl ester (5e). Compounds 5d and 5e were obtained
as colorless oils in 6% and 12% yield, respectively. Com-
pound 5d: Rf = 0.49 (EtOAc/pet. ether, 1:1);
1H NMR d
7.26 (d, J = 9.1 Hz, 1H), 6.80 (d, J = 2.9 Hz, 1H), 6.54
(dd, J = 9.1, 2.9 Hz, 1H), 5.84 (d, J = 1.8 Hz, 1H), 4.73
(m, 1H), 4.34 (d, J = 1.8 Hz, 1H), 4.02 (d, J = 6.6 Hz,
1H), 3.86 (m, 1H), 3.71 (s, 3H), 3.65 (d, J = 12.1 Hz,
1H), 3.26 (d, J = 12.1 Hz, 1H); 13C NMR d 168.9 (s),
148.5 (s), 133.2 (s), 130.6 (d), 122.0 (s), 114.6 (d), 112.3
(d), 99.0 (d), 71.8 (d), 67.4 (t), 62.2 (d), 52.3 (q), 48.2
(t); MS m/z 319 (M+, 11), 317 (M+, 17), 260 (17), 258
(23), 176 (14), 174 (94) 172 (100). Anal. Calcd for
C13H13Cl2NO4: C, 49.08; H, 4.12; N, 4.40. Found: C,
48.87; H, 4.08; N, 4.46.
Compound 5e: Rf = 0.42 (EtOAc/pet. ether, 1:1);
1H
NMR d 7.27 (d, J = 8.8 Hz, 1H), 6.76 (d, J = 2.9 Hz,
1H), 6.45 (dd, J = 8.8, 2.9 Hz, 1H), 5.81 (d, J = 2.9 Hz,
1H), 4.82 (m, 1H), 4.12 (d, J = 7.0 Hz, 1H), 4.05 (d,
J = 2.9 Hz, 1H), 3.93 (m, 1H), 3.76 (s, 3H), 3.56 (d,
J = 11 Hz, 1H), 3.39 (dd, J = 11, 3.7 Hz, 1H); 13C
NMR d 168.6 (s), 147.9 (s), 132.6 (s), 130.1 (d), 122.5
(s), 115.8 (d), 133.3 (d), 98.0 (d), 70.9 (d), 67.0 (t), 62.5
(d), 52.4 (q), 51.5 (t); MS m/z 319 (M+, 9), 317 (M+,
12), 260 (5), 258 (8), 176 (10), 174 (73), 172 (100). Anal.
Calcd for C13H13Cl2NO4: C, 49.08; H, 4.12; N, 4.40.
Found: C, 48.85; H, 4.07; N, 4.37.
3.2.9. (1R,4S,5S)-N-(4-Chloro-phenyl)-6,8-dioxa-3-aza-
bicyclo[3.2.1]octane-4-exo-carboxylic acid methyl ester
(5f) and (1R,4R,5S)-N-(4-chloro-phenyl)-6,8-dioxa-3-
aza-bicyclo[3.2.1]octane-4-endo-carboxylic acid methyl
ester (5g). Compounds 5f and 5g were obtained as oils
in 10% and 16% yield, respectively. Compound 5f:
Rf = 0.6 (EtOAc/pet. ether, 1:1);
1H NMR d 7.18 (d,
J = 9.2 Hz, 2H), 6.64 (d, J = 9.2 Hz, 2H), 5.83 (s, 1H),
4.75 (m, 1H), 4.37 (s, 1H), 4.03 (d, J = 6.6 Hz, 1H),
3.85 (t, J = 6.6 Hz, 1H), 3.68 (s, 3H), 3.65 (m, 1H),
3.27 (d, J = 11.6 Hz, 1H); 13C NMR d 169.2 (s), 148.1
(s), 129.1 (d), 124.9 (s), 114.0 (d), 99.0 (d), 72.1 (d),
67.4 (t), 62.4 (d), 52.2 (q), 48.2 (t); MS m/z 285
(M+ + 2, 9), 283 (M+, 29), 226 (9), 224 (29), 199 (17),
197 (52), 140 (42), 138 (100), 113 (17), 111 (48), 85
(32), 59 (10), 57 (92). Anal. Calcd for C13H14ClNO4:
C, 55.04; H, 4.97; N, 4.94. Found: C, 54.97; H, 4.86;
N, 4.85.
Compound 5g: Rf = 0.51 (EtOAc/pet. ether, 1:1);
1H
NMR d 7.20 (d, J = 9.0 Hz, 2H), 6.61 (d, J = 9.0 Hz,
2H), 5.79 (d, J = 2.8 Hz, 1H), 4.79 (m, 1H), 4.16 (d,
J = 6.2 Hz, 1H), 4.03 (d, J = 2.8 Hz, 1H), 3.92 (t,
J = 6.2 Hz, 1H), 3.74 (s, 3H), 3.59 (d, J = 11.4 Hz,
1H), 3.34 (dd, J = 11.4, 3.2 Hz, 1H); 13C NMR d 169.0
(s), 147.3 (s), 128.7 (d), 124.9 (s), 115.8 (d), 98.4 (d),
71.4 (d), 67.1 (t), 63.0 (d), 52.4 (q), 52.2 (t); MS m/z
285 (M+ + 2, 5), 283 (M+, 15), 226 (4), 224 (12), 199
(11), 197 (30), 140 (37), 138 (100), 113 (14), 111 (45),
85 (16), 59 (11), 57 (50). Anal. Calcd for C13H14ClNO4:
C, 55.04; H, 4.97; N, 4.94. Found: C, 54.91; H, 4.87; N,
4.88.
3.2.10. (1R,4S,5S)-N-(4-Iodo-phenyl)-6,8-dioxa-3-aza-bi-
cyclo[3.2.1]octane-4-exo-carboxylic acid methyl ester (5h)
and (1R,4R,5S)-N-(4-iodo-phenyl)-6,8-dioxa-3-aza-bicy-
clo[3.2.1]octane-4-endo-carboxylic acid methyl ester (5i).
Compounds 5h and 5i were obtained as oils in 12% and
13% yield, respectively. Compound 5h: Rf = 0.6 (EtOAc/
pet. ether, 1:1); 1H NMR (400 MHz) d 7.49 (d,
J = 8.8 Hz, 2H), 6.49 (d, J = 8.8 Hz, 2H), 5.83 (d,
J = 1.6 Hz, 1H), 4.74 (m, 1H), 4.36 (d, J = 1.6 Hz,
1H), 4.02 (d, J = 6.8 Hz, 1H), 3.85 (t, J = 6.8 Hz, 1H),
3.68 (s, 3H), 3.64 (d, J = 10 Hz, 1H), 3.28 (d,
J = 11.6 Hz, 1H); 13C NMR d 169.2 (s), 148.9 (s),
137.9 (d), 115.0 (d), 99.0 (d), 80.7 (s), 72.0 (d), 67.4 (t),
62.1 (d), 52.2 (q), 47.9 (t); MS m/z 375 (M+, 45), 316
(18), 289 (60), 230 (85), 203 (25), 76 (86), 57 (100). Anal.
Calcd for C13H14INO4: C, 41.62; H, 3.76; N, 3.73.
Found: C, 41.57; H, 3.66; N, 3.64.
Compound 5i: Rf = 0.51 (EtOAc/pet. ether, 1:1);
1H
NMR d 7.50 (d, J = 9.2 Hz, 2H), 6.44 (d, J = 9.2 Hz,
2H), 5.80 (d, J = 3.4 Hz, 1H), 4.80 (m, 1H), 4.13 (d,
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J = 6.6 Hz, 1H), 4.03 (d, J = 3.4 Hz, 1H), 3.92 (t,
J = 6.6 Hz, 1H), 3.74 (s, 3H), 3.58 (d, J = 11.4 Hz,
1H), 3.35 (dd, J = 11.4, 3.8 Hz, 1H); 13C NMR d 169.1
(s), 148.7 (s), 137.6 (d), 116.5 (d), 98.4 (d), 81.9 (s),
71.4 (d), 67.3 (t), 62.9 (d), 52.6 (q), 51.9 (t); MS m/z
375 (M+, 38), 316 (11), 289 (54), 230 (87), 203 (25), 76
(100), 59 (46), 57 (87). Anal. Calcd for C13H14INO4:
C, 41.62; H, 3.76; N, 3.73. Found: C, 41.51; H, 3.70;
N, 3.68.
3.2.11. (1R,4S,5S)-N-(4-Bromo-phenyl)-6,8-dioxa-3-aza-
bicyclo[3.2.1]octane-4-exo-carboxylic acid methyl ester
(5j) and (1R,4R,5S)-N-(4-bromo-phenyl)-6,8-dioxa-3-
aza-bicyclo[3.2.1]octane-4-endo-carboxylic acid methyl
ester (5k). Compounds 5j and 5k were obtained as oils
in 13% and 14% yield, respectively. Compound 5j:
Rf = 0.66 (EtOAc/pet. ether, 1:1);
1H NMR d 7.32 (d,
J = 8.8 Hz, 2H), 6.60 (d, J = 8.8 Hz, 2H), 5.83 (d,
J = 1.8 Hz, 1H), 4.73 (m, 1H), 4.37 (d, J = 1.8 Hz,
1H), 4.03 (d, J = 6.6 Hz, 1H), 3.85 (m, 1H), 3.68 (s,
3H), 3.65 (m, 1H), 3.27 (m, 1H); 13C NMR d 169.2
(s), 147.8 (s), 132.0 (d), 114.5 (d), 111.2 (s), 99.0 (d),
72.0 (d), 67.4 (t), 62.3 (d), 52.2 (q), 48.1 (t); MS m/z
329 (M+ + 2, 42), 327 (M+, 43), 270 (45), 268 (45), 243
(98), 241 (100), 184 (4.3), 182 (4.8), 172 (2), 157 (5),
155 (5), 117 (6.5), 91 (34), 85 (9), 59 (24), 57 (63). Anal.
Calcd for C13H14BrNO4: C, 47.58; H, 4.30; N, 4.27.
Found: C, 47.67; H, 4.25; N, 4.16.
Compound 5k: Rf = 0.58 (EtOAc/pet. ether, 1:1);
1H
NMR d 7.33 (d, J = 9.0 Hz, 2H), 6.55 (d, J = 9.0 Hz,
2H), 5.8 (d, J = 3.2 Hz, 1H), 4.80 (m, 1H), 4.15 (d,
J = 6.8 Hz, 1H), 4.03 (d, J = 3.2 Hz, 1H), 3.92 (t,
J = 6.8 Hz 1H), 3.74 (s, 3H), 3.58 (d, J = 11.0 Hz, 1H),
3.34 (dd, J = 11.0, 3.0 Hz, 1H); 13C NMR d 169.1 (s),
147.6 (s), 131.8 (d), 116.2 (d), 112. 3 (s), 98.5 (d), 71.5
(d), 67.3 (t), 63.1 (d), 52.6 (q), 52.2 (t); MS m/z 329
(M+ + 2, 9), 327 (M+, 9), 270 (7.2), 268 (7.4), 243
(25.4), 241 (27), 184 (58), 182 (61), 157 (16), 155 (20),
57 (100). Anal. Calcd for C13H14BrNO4: C, 47.58; H,
4.30; N, 4.27. Found: C, 47.45; H, 4.21; N, 4.19.
3.2.12. (1R,4S,5S)-N-(Phenyl)-6,8-dioxa-3-aza-bicy-
clo[3.2.1]octane-4-exo-carboxylic acid methyl ester (5l).
A yellowish oil was obtained (14%). Rf = 0.47 (EtOAc/
pet. ether, 1:2); 1H NMR d 7.24 (m, 2H), 6.82 (t,
J = 7.3 Hz, 1H), 6.72 (d, J = 8.8 Hz, 2H), 5.83 (d,
J = 1.4 Hz, 1H), 4.75 (m, 1H), 4.43 (d, J = 1.4 Hz,
1H), 4.04 (d, J = 6.3 Hz, 1H), 3.85 (t, J = 6.3 Hz, 1H),
3.70 (m, 1H), 3.68 (s, 3H), 3.34 (d, J = 11.8 Hz, 1H);
13C NMR d 169.6 (s), 148.7 (s), 129.3 (d), 118.9 (d),
112.8 (d), 99.2 (d), 72.2 (d), 67.4 (t), 62.3 (d), 52.1 (q),
48.0 (t); MS m/z 249 (M+, 30), 190 (21), 163 (25),
117(8), 104 (100), 91 (13), 77 (88). Anal. Calcd for
C13H15NO4: C, 62.64; H, 6.07; N, 5.62. Found: C,
62.57; H, 5.98; N, 5.59.
3.2.13. (1R,4S,5S)-N-(4-Fluoro-phenyl)-6,8-dioxa-3-aza-
bicyclo[3.2.1]octane-4-exo-carboxylic acid methyl ester
(5m). A brown oil was obtained (30%). Rf = 0.48
(EtOAc/pet. ether, 1:2; 1% Et3N);
1H NMR d 6.95 (m,
2H), 6.67 (dd, J = 9.0, 4.4 Hz, 2H), 5.82 (d, J = 2.0 Hz,
1H), 4.72 (m, 1H), 4.36 (d, J = 2.0 Hz, 1H), 4.05 (d,
J = 6.6 Hz, 1H), 3.85 (t, J = 6.6 Hz, 1H), 3.70 (m, 1H),
3.67 (s, 3H), 3.23 (dd, J = 9.8, 1.8 Hz, 1H); 13C NMR
d 169.3 (s), 156.4 (s, JF = 236 Hz), 145.1 (s), 115.6 (d,
JF = 22 Hz), 114.2 (d, JF = 7.5 Hz), 99.1 (d), 72.2 (d),
67.4 (t), 62.9 (d), 52.1 (q), 48.5 (t); MS m/z 267 (M+,
29), 208 (33), 181 (51), 122 (100), 109 (10), 75 (26), 59
(9), 57 (12). Anal. Calcd for C13H14FNO4: C, 58.42;
H, 5.28; N, 5.24. Found: C, 58.38; H, 5.14; N, 5.17.
3.3. Biology
3.3.1. Receptor preparation. The membranes suspended
in 50 mM Tris–HCl, pH 7.4, 10% sucrose for dopamine
transporter and 50 mM Tris–HCl, pH 7.4, 5 mM KCl,
10% sucrose for serotonin transporter were thawed,
diluted with binding buffer (50 mM Tris–HCl, 100 mM
NaCl, pH 7.4, for hDAT and 50 mM Tris–HCl,
120 mM NaCl, 5 mM KCl, pH 7.4, for hSERT), and
processed with a Polytron homogenizer (Ultraturrax
T8, IKA, Wilmington, NC).
3.3.2. Dopamine and serotonin transporters’ binding
affinity assays. Competition binding studies were per-
formed with a fixed concentration of radioligand
([3H]WIN35,428 8 nM to label DAT and [3H]citalopram
1 nM to label SERT) and concentrations ranging from
100 lM to 1 nM of the tested molecules. Stock solutions
of 1 mM were prepared by dissolving the tested com-
pounds in an EtOH/H2O mixture where the EtOH final
concentration was not superior to 2%. A 0.5% polyethy-
lenimine solution (0.05 mL to each well) was added to
UniFilter-96 GF/C glass fiber filter plates (Perkin-Elmer
Life Sciences, Boston, MA) and the plates were allowed
to incubate at 4  C for 2 h. All assays were performed in
triplicate on 96-well microplates in a final volume of
0.2 mL, each containing the following species: 0.04 mL
of radioligand, 0.04 mL of tested compound, 0.02 mL
of diluted membrane suspension, and 0.10 mL of incu-
bation buffer. Non-specific binding was defined as radi-
oligand bound in the presence of an excess (10 lM final)
of GBR12909 or Citalopram in DAT and SERT assays,
respectively. After incubation for 2 h, binding was ter-
minated by rapid filtration over a FilterMate Harvester
system (Perkin-Elmer Life Sciences, Boston, MA). Fil-
ters were washed nine times with the cold buffer
50 mM Tris–HCl, 0.9% NaCl, pH 7.4, for DAT and
0.9% NaCl for SERT, dried, and counted in the Top-
Count NXT microplate scintillation counter (Perkin-
Elmer Life Sciences, Boston, MA) using 0.25 mL of
MicroScint-40 liquid scintillation (Perkin-Elmer Life
Sciences, Boston, MA).
3.3.3. Data analysis. Relative affinity values (IC50) were
determined by fitting binding inhibition values by non-
linear regression using GraphPad curve fitting software
(PRISM, San Diego, California).
3.4. Molecular modeling
Calculations were performed using SPARTAN ver-
sion 5.147 running on a SGI IRIX 6.5 workstation.
Conformational searches of O-1072 and 5d were car-
ried out using Monte Carlo method within
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MMFF94 force field,48 and the AM1 semiempirical
method49 was used to optimize the global minimum
conformer. The geometry of the most abundant min-
imum energy conformer was successively subjected to
ab initio single point calculation of the electronic
properties at the 3-21G*/HF level50 of quantum
chemical theory. The electrostatic potentials were
sampled over the entire accessible surface of the
molecules (corresponding roughly to a van der
Waals contact surface).
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